Fennec Pharmaceuticals to Present New PEDMARK® Data at ASCO 2026, Highlighting Expanded Clinical Interest
FENC sits 29% above its 52-week low of $5.17.
Summary
Fennec Pharmaceuticals announced the acceptance of four abstracts for its key product, PEDMARK®, at the 2026 ASCO Annual Meeting, showcasing new clinical data and expanding interest in preventing cisplatin-induced hearing loss.
Key Events · Product Development and Regulatory · FENC
-
PEDMARK® Abstracts Accepted for ASCO 2026
Four abstracts evaluating PEDMARK® (sodium thiosulfate injection) were accepted for presentation or publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
-
New Clinical Data Presented
Presentations will include results from the Japanese Children's Cancer Group STS-J01 Study, a Phase 1 trial for metastatic germ cell tumor, real-world feasibility data, and audiometric outcomes in adults with head and neck cancer.
-
Increased Product Visibility and Validation
The acceptance of multiple abstracts at a major oncology conference provides significant clinical validation and increased visibility for Fennec's primary product, supporting potential market expansion and continued sales momentum.
Analysis · FENC · Life Sciences
This 8-K announces the acceptance of four abstracts for presentation or publication at the 2026 ASCO Annual Meeting, focusing on PEDMARK® (sodium thiosulfate injection). The abstracts include new data from a Japanese study, a Phase 1 trial for metastatic germ cell tumor, real-world feasibility in young adults, and audiometric outcomes in adults with head and neck cancer. This news provides significant clinical validation and increased visibility for Fennec's key product, PEDMARK®, potentially broadening its perceived utility beyond its current pediatric indication and supporting continued sales growth, building on the strong sales reported in the last 10-K.
At the time of this filing, FENC was trading at $6.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $230.3M. The 52-week trading range was $5.17 to $9.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.